ClinConnect ClinConnect Logo
Search / Trial NCT00763386

A Study to Compare the NexGen LPS and LPS-Flex Knee Implants

Launched by ZIMMER BIOMET · Sep 29, 2008

Trial Information

Current as of April 27, 2025

Completed

Keywords

Total Knee Arthroplasty Osteoarthritis Knee

ClinConnect Summary

This study will compare the clinical results of the NexGen LPS femoral component with the higher flexion potential of the NexGen LPS-Flex femoral component in all patients with degenerative joint disease that require total knee arthroplasty. The primary variable of interest is postoperative range of motion achieved with the two devices, which are implanted with slightly different surgical techniques in patients who may also be subjected to different rehabilitation programs depending on the device they are assigned.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age, 21-80 years
  • Sex, Males and females will be included
  • BMI less than or equal to 39 and calf-thigh less than or equal to 90 degrees
  • Stable health, the patient would be able to undergo surgery and participate in the follow-up program based on physical examination and medical history.
  • Patient is willing and able to cooperate in follow-up therapy.
  • Patient exhibits preoperative radiographic evidence of joint degeneration consistent with TKA that cannot be treated in non-operative fashion.
  • Patient has stable and functional collateral ligaments.
  • Patient has potential to perform higher than average range of motion activities.
  • Operative side range of motion flexion greater than or equal to 90 degrees.
  • Severe knee pain and disability due to degenerative joint disease.
  • Patient or patient's legal representative has signed the Informed Consent form.
  • Exclusion Criteria:
  • Previous history of infection in the affected joint.
  • Previously failed knee endoprosthesis of any kind.
  • Charcot joint disease or other severe neurosensory deficits.
  • Previous patellectomy.
  • Patient is skeletally immature.
  • Grossly insufficient femoral or tibial bone stock.
  • Patient is pregnant.
  • Varus or valgus deformity greater than 20 degrees.
  • Fixed flexion deformity greater than 15 degrees.
  • Previous high tibial osteotomy.
  • Previous femoral osteotomy.
  • Patient is a poor compliance risk - currently treated for ethanol or drug abuse, physical or mental handicap, etc.
  • Loss of musculature or absence of musculoligamentous supporting structures required for adequate soft tissue balance.

About Zimmer Biomet

Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.

Locations

Durham, North Carolina, United States

Birmingham, Alabama, United States

Montreal, Quebec, Canada

Philadelphia, Pennsylvania, United States

Decatur, Georgia, United States

Springfield, Illinois, United States

Mooresville, Indiana, United States

Indianapolis, Indiana, United States

Charlotte, North Carolina, United States

Allentown, Pennsylvania, United States

Greenville, South Carolina, United States

Spartanburg, South Carolina, United States

Nashville, Tennessee, United States

Galveston, Texas, United States

Charlottesville, Virginia, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials